comparemela.com

Latest Breaking News On - Rocket pharmaceuticals stock down - Page 1 : comparemela.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Receives New Coverage from Analysts at The Goldman Sachs Group

The Goldman Sachs Group started coverage on shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) in a report published on Tuesday, MarketBeat Ratings reports. The firm issued a neutral rating and a $39.00 price target on the biotechnology company’s stock. RCKT has been the topic of several other reports. UBS Group cut their price objective […]

Cantor Fitzgerald Reiterates Overweight Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They currently have a $65.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 123.91% from the stock’s previous close. […]

StockNews com Initiates Coverage on Rocket Pharmaceuticals (NASDAQ:RCKT)

Equities researchers at StockNews.com began coverage on shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) in a note issued to investors on Thursday. The firm set a “sell” rating on the biotechnology company’s stock. A number of other analysts also recently issued reports on the stock. Canaccord Genuity Group dropped their price objective on […]

Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Down 6 4%

Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) were down 6.4% during trading on Thursday . The company traded as low as $19.81 and last traded at $19.93. Approximately 209,682 shares traded hands during trading, a decline of 77% from the average daily volume of 906,736 shares. The stock had previously closed at […]

Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded at StockNews com

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) was upgraded by StockNews.com to a “sell” rating in a research note issued to investors on Monday. Other equities analysts also recently issued reports about the company. Canaccord Genuity Group cut their target price on Rocket Pharmaceuticals from $49.00 to $47.00 and set a “buy” rating on the […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.